Required warfarin dose and time in therapeutic range in patients with diagnosed Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH).
Warfarin has been widely used to treat thromboembolism. The effect of nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH), on warfarin dosing remains unknown. This study aims to examine the effects of NAFLD/NASH on the average daily dose (ADD) of warfarin and the time in...
Enregistré dans:
Auteurs principaux: | Xuerong Wen, Shuang Wang, Tracey H Taveira, Fatemeh Akhlaghi |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Public Library of Science (PLoS)
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/a649b86cf1e7462fa009bb69d0a8f7c2 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Endoscopic duodenal mucosal resurfacing for nonalcoholic steatohepatitis (NASH): a pilot study
par: Alia Hadefi, et autres
Publié: (2021) -
Circulating miRNA is a useful diagnostic biomarker for nonalcoholic steatohepatitis in nonalcoholic fatty liver disease
par: Tae Hyung Kim, et autres
Publié: (2021) -
Metabolic causes and consequences of nonalcoholic fatty liver disease (NAFLD)
par: Paria Zarghamravanbakhsh, et autres
Publié: (2021) -
Association between Equol Production Status and Nonalcoholic Steatohepatitis
par: Takemi Akahane, et autres
Publié: (2021) -
Subclinical steatohepatitis and advanced liver fibrosis in health examinees with nonalcoholic fatty liver disease (NAFLD) in 10 South Korean cities: A retrospective cross-sectional study.
par: Eun-Hee Nah, et autres
Publié: (2021)